The Fuchs Endothelial Corneal Dystrophy (FECD) drugs in development market research report provides comprehensive information on the therapeutics under development for Fuchs Endothelial Corneal Dystrophy (FECD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Fuchs Endothelial Corneal Dystrophy (FECD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Fuchs Endothelial Corneal Dystrophy (FECD) and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Fuchs Endothelial Corneal Dystrophy (FECD) by 15 companies/universities/institutes. The top development phase for Fuchs Endothelial Corneal Dystrophy (FECD) is preclinical with five drugs in that stage. The Fuchs Endothelial Corneal Dystrophy (FECD) pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Fuchs Endothelial Corneal Dystrophy (FECD) pipeline products market are: ActualEyes, Prime Medicine and Kuria Therapeutics.
The key targets in the Fuchs Endothelial Corneal Dystrophy (FECD) pipeline products market include Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1), Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1), and Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2).
The key mechanisms of action in the Fuchs Endothelial Corneal Dystrophy (FECD) pipeline product include Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1) Inhibitor with two drugs in Phase III. The Fuchs Endothelial Corneal Dystrophy (FECD) pipeline products include five routes of administration with the top ROA being Ophthalmic and six key molecule types in the Fuchs Endothelial Corneal Dystrophy (FECD) pipeline products market including Small Molecule, and Gene Therapy.
Fuchs Endothelial Corneal Dystrophy (FECD) overview
Fuchs endothelial corneal dystrophy (FECD) is characterized by progressive loss of corneal endothelial cells, thickening of Descement’s membrane and deposition of extracellular matrix in the form of guttae. When the number of endothelial cells becomes critically low, the cornea swells and causes loss of vision. It affects the thin layer of cells that line the back part of the cornea. This layer is called the endothelium. The disease occurs when these cells slowly start to die off. Symptoms iniclude reduction of corneal clarity, Nyctalopia, visual loss.
For a complete picture of Fuchs Endothelial Corneal Dystrophy (FECD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
